Renibus Therapeutics Announces FDA Orphan Drug Designation for Veverimer for the Treatment of Anti-glomerular Basement Membrane Disease (anti-GBM)

Renibus Therapeutics Announces FDA Orphan Drug Designation for Veverimer for the Treatment of Anti-glomerular Basement Membrane Disease (anti-GBM) Southlake, Texas, May [27], 2025, (PR NEWSWIRE) – Renibus Therapeutics® (“Renibus”), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to veverimer for the treatment of anti-glomerular basement membrane disease (anti-GBM), an […] The post Renibus Therapeutics Announces FDA Orphan Drug Designation for Veverimer for the Treatment of Anti-glomerular Basement Membrane Disease (anti-GBM) appeared first on Re